



CSAM Health Group AS

Quarterly Report Q3-22 30 November 2022



CSAM's software facilitates life-changing milestones




Vital solutions for 500 healthcare and emergency response organisations across 25 countries



Developing diversified and growing business areas



















+4,8%

Recurring revenues: ~71 MNOK vs ~68 MNOK in Q3-21





+0,0%

Income ~86.5 MNOK vs ~86.5 MNOK in Q3-21



2,4%

Organic growth Q3-22 vs Q3-21 YTD: 5.4%



92%

92% gross margin vs 92% gross margin in Q3-21



5%

Reported EBITDA was 4.7 MNOK vs 20.1 MNOK in Q3-21



12%




Reported sales outside the Nordics increased to 12% vs 8% in Q3-21






Growing the EBITDA margin through BIB





Current BIB integration project portfolio



Decentralised, scalable and ready to grow





Project Triginta: From 5% EBITDA margin in Q3-22 to ~30% in Q3-23



















BIB


FERTS OFT






Decentralised Buy, Integrate & Build processes

Prepared for the next leg






Where we came from and where we are heading






From Nordic to Pan-European - and beyond

Q3-2021 Q3-2022










CSAM's recurring software revenues are steadily increasing





Favourable revenue mix


High license sales in Q3-21 combined with low other income resulted in flat Q/Q development


NOKm

Total revenue, Q/Q development

Recurring revenue, Q/Q development

NOKm








Gross margin continue to be above 90%



Cost base development Q/Q (NOKm)




Comments

- Gross margin 92%
- Profitability temporarily hampered by reorganisation into business units
- Significant increase in number of FTEs as a consequence of recruitment activities necessary to handle delivery pipeline (driving licence sales and recurring revenue long term)
- Project Triginta will restore profitability towards 30% EBITDA margin in Q3-23




Margins are temporarily diluted





Net working capital development




Comments

- CSAM has a communicated NWC target of -10% or better
- When acquiring companies, it takes some time before CSAMs NWC policies are applied in the acquired companies, hence NWC development will vary



CSAM investors per November 2022






Concluding remarks

- 1. Organic growth
- 2. M&A high activity, but will remain disciplined
- 3. Profitability
- 4. Decentralised and empowered organisation
- 5. Reporting per Business Area from Q1 2023



Prepared for the next leg





Subscribe to our newsletter

